GMAB — Genmab A/S

Genmab Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Increased by 19% to $3.7 billion, driven by strong performance in both royalty income and sales of proprietary medicines.
• Sales of Proprietary Medicines: Reached $632 million, a 54% year-over-year increase, contributing approximately 28% to total revenue growth.
• Operating Profit: Rose to $1.26 billion, reflecting strong operational execution and increased operating leverage.
• 2026 Guidance: Projected total revenue growth of 14%, with expectations for DARZALEX net sales between $15.6 billion and $16.4 billion. Operating profit expected to be around $1.15 billion at the midpoint.

2. Strategic Updates and Business Highlights

• Pipeline Development: Significant progress in late-stage pipeline with EPKINLY, Rina-S, and petosemtamab, all showing multibillion-dollar potential.
• EPKINLY: Received FDA approval for second-line follicular lymphoma, with strong sales growth and positive physician feedback. Positioned as a core therapy in B-cell malignancies.
• Rina-S: Expanded development with three Phase III trials initiated, targeting multiple gynecologic cancers.
• Acquisition of Merus: Enhanced late-stage portfolio with petosemtamab, which has shown promising data in head and neck cancer.
• Commercialization Success: Expanded market presence in Europe, achieving key approvals for TIVDAK and EPKINLY.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipation of multiple registrational data readouts that could lead to significant product launches in 2027.
• Focus Areas: Continued investment in commercialization capabilities and late-stage development to support upcoming launches and maximize the potential of existing therapies.
• Long-term Growth: Confidence in sustainable growth driven by a diversified revenue base and robust pipeline.

4. Bad News, Challenges, or Points of Concern

• EPCORE DLBCL-1 Trial Results: While the trial showed positive progression-free survival (PFS), it missed the overall survival (OS) endpoint, raising concerns about the implications for regulatory approval and future trials.
• Regulatory Uncertainty: Ongoing discussions with health authorities regarding the confirmatory nature of the trial results, particularly in light of the COVID-19 pandemic's impact on data.
• Market Competition: Potential competitive pressures from other therapies in the B-cell malignancy space, particularly with new entrants and established therapies like POLIVY.

5. Notable Q&A Insights

• Next Steps for EPKINLY: Discussions with regulatory agencies are ongoing regarding the implications of the EPCORE DLBCL-1 trial results, with confidence in upcoming Phase III trials.
• Rina-S Opportunity: Management reiterated a peak sales potential of over $2 billion, with ongoing Phase III trials expected to validate its efficacy.
• Commercial Strategy: The company is focused on strategic investments to strengthen its commercialization efforts, particularly as it prepares for multiple product launches.
• Market Positioning: EPKINLY is expected to achieve blockbuster status, with a strong emphasis on expanding its use in earlier lines of therapy.

Overall, Genmab demonstrated solid financial performance in 2025, with a clear strategy for growth and a promising pipeline, despite facing regulatory challenges and competitive pressures in the oncology market.